

Q3, Level 2, Unit 1, Quad Central, Triq l-Esportaturi, Central Business District, Malta

30<sup>th</sup> April 2026

## **COMPANY ANNOUNCEMENT**

Errata Corrigé relative to Company Announcement Ref No. BRW38 issued by Brown's Pharma Holdings p.l.c. (the '**Company**') pursuant to the Capital Markets Rules issued by the Malta Financial Services Authority.

---

### **Quote**

The Company hereby announces that the fourth item under 'Results of Annual General Meeting' of the abovementioned Company Announcement Ref No. BRW38 is to be corrected as indicated hereunder. For ease of reference, the entire Company Announcement, duly corrected as aforesaid, is being reproduced in its entirety:

### **Results of Board of Directors' Meeting and Annual General Meeting**

The Company makes reference to the Board of Directors' Meeting and the Annual General Meeting held on the 29<sup>th</sup> April 2026.

#### **Results of Board of Directors' Meeting**

The Company hereby announces that, during the meeting of its Board of Directors held on the 29<sup>th</sup> April 2026, the Board of Directors resolved to approve the Company's annual report and audited financial statements for the year ended 31<sup>st</sup> December 2025.

The Company refers to the financial projections for the year ended 31<sup>st</sup> December 2025 included in the Financial Analysis Summary, and to the approved annual report and audited consolidated financial statements of the Company for the same financial year.

For the year ended 31<sup>st</sup> December 2025, the Group reported consolidated revenue of €75.053 million and profit after tax of €4.037 million. This compares to projected revenue of €61.860 million and projected net income of €3.941 million. Accordingly, actual revenue exceeded the projected amount by €13.193 million, equivalent to 21.33%, while profit after tax exceeded the projected amount by €0.096 million, equivalent to 2.44%.

Q3, Level 2, Unit 1, Quad Central, Triq l-Esportaturi, Central Business District, Malta

The positive revenue variance was principally attributable to higher-than-projected activity levels across the Group. This reflected continued growth within the Malta retail operations, increased contribution from Mediva Pharma Limited, and higher sales volumes generated during the year.

The more limited variance at profit after tax level reflects the impact of the Group's cost structure and revenue mix. In particular, the increase in revenue included a greater contribution from lower-margin wholesale activity, which resulted in a reduction in the Group's gross margin when compared to the prior year. This was partly offset by operating leverage, as the Group's operating profit increased at a higher rate than revenue. However, the benefit of the higher revenue base was moderated by increased cost of sales, operating expenses, depreciation and amortisation, finance costs and taxation.

Notwithstanding these cost and margin effects, the Group's actual profit after tax remained ahead of the projected amount for 2025. The Directors consider the variance to be reflective of a year of stronger-than-projected trading activity, supported by revenue growth across the Group's operating base and improved absorption of fixed operating costs as volumes increased.

A copy of the said Annual Report and Audited Financial Statements can be found by accessing this [link](#).

Attached to this Company Announcement is a Director's Declaration on ESEF Annual Financial Reports.

### **Results of Annual General Meeting**

The Company hereby announces that the members of the Company approved and adopted the following resolutions at its Annual General Meeting:

1. Annual Report and Audited Financial Statements

That the Company's Annual Report and Audited Financial Statements for the financial year ended 31<sup>st</sup> December 2025, as duly approved by the Board of Directors of the Company, have been approved by the members of the Company.

2. Re-appointment of the Auditors

That the re-appointment of the auditors of the Company has been approved and that the Directors of the Company were authorised to fix their remuneration.

Q3, Level 2, Unit 1, Quad Central, Triq l-Esportaturi, Central Business District, Malta

3. Re-appointment of the Directors

That the current directors have been re-appointed.

4. Dividend

That a net dividend of €1,618,832 has been declared.

**Unquote**

By order of the Board

A handwritten signature in blue ink, appearing to read 'J.C. Farrugia', is written over a set of three horizontal blue lines.


**Dr Jean C. Farrugia**  
**Company Secretary**

30<sup>th</sup> April 2026

## DIRECTORS' DECLARATION ON ESEF ANNUAL FINANCIAL REPORTS


We, Mr Alexander Fenech, Mr David Camilleri and Mr Paul Camilleri, in our capacity as Directors of Brown's Pharma Holdings plc (C 95118), hereby **certify**:

- i. That the Annual Financial Report for the year ended 31<sup>st</sup> December 2025 has been approved by the Board of Directors of the Company and is hereby being made available to the public.
- ii. That the Annual Financial Report has been prepared in terms of the applicable rules and regulations, including the Commission Delegated Regulation on the European Single Electronic Format ("ESEF")<sup>1</sup> and the Capital Markets Rules<sup>2</sup>.
- iii. That the Audit Report on the ESEF Annual Financial Report is an exact copy of the original signed by the auditor and that no alterations have been made to the audited elements of the Annual Financial Report including the annual financial statements.
- iv. That the Annual Financial Report shall serve as the official document for the purposes of the Capital Markets Rules and the Companies Act (Chapter 386 of the Laws of Malta).

Signed by:  
  
36490B0A493045D...

Mr Alexander Fenech

Director

DocuSigned by:  
  
C440D9EC123D439...

Mr David Camilleri

Director

DocuSigned by:  
  
AF156D2705C543D...

Mr Paul Camilleri

Director

---

<sup>1</sup> Commission Delegated Regulation 2019/815 on the European Single Electronic Format, as may be further amended from time to time.

<sup>2</sup> Capital Markets Rules as issued by the Malta Financial Services Authority (MFSA).